Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $8.8MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading |
|---|
Company profile
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Relationship |
|---|
| Date |
|---|
| Transaction |
|---|
| Cost |
|---|
| Shares |
|---|
| Value |
|---|
| Shares total |
|---|
| SEC Form 4 |
|---|
| Kaplan Johanne | Chief Development Officer | Aug 05 '26 | Buy | $13.30 | 2,280 | $30,324 | 6,221 | Aug 07 04:00 PM |
| Kirwin Patrick D. | Director | Apr 22 '26 | Buy | $11.33 | 4,000 | $45,320 | 4,653 | Apr 23 09:25 PM |
| Williams Eugene | Director | Mar 05 '26 | Buy | $24.40 | 2,000 | $48,800 | 12,397 | Mar 06 07:28 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.